Survival and Stage in Lung Cancer

Aim of study: Lung cancer is the leading cause of cancer death worldwide. Although the 5-year survival rates of for non-small cell lung carcinoma (NSCLC) ranges from 20% to 70%. The present study investigates the rates of early recurrence in a total of 83 patients operated for NSCLC and presents the related findings in reference to the data available in the literature. Materials and Methods: Patients who underwent lung resection for malignancy between March 2019 and September 2021 were retrospectively examined. The patient data, including age, gender, presence of preoperative chemotherapy administration, operations performed, operation dates, pathology results, postoperative staging, survival, and relapses, were documented. Ethical approval for this study was obtained from the ethics committee of Ankara Bilkent City Hospital. Approval number is E1-20-817 Results: A total of 83 patients who underwent lung resection for malignancy between March 2019 and September 2021 were examined. The patients had a median age of 62 years. Of the total number of patients four patients developed recurrence and 79 continued their follow-up without any recurrence. Of the patients who underwent lung resection, eight (9.6%) patients died within the first postoperative 2-year period. The mean survival period of these eight patients was 14.6 months (7–20 months). Conclusion: Although various parameters, such as age, gender, pathological type, and location of the tumor are examined and compared, according to the available data on the long-term survival of surgical patients, it is known that the only parameter that affects survival is the pathological stage of the patient. Amaç: Akciğer kanseri, dünya çapında kanser ölümlerinin önde gelen nedenidir. Küçük hücreli dışı akciğer kanseri (KHDAK) için 5 yıllık sağkalım oranları %20 ile %70 arasında değişmektedir. Bu çalışmada KHDAK nedeniyle opere edilen toplam 83 hastada erken nüks oranları araştırılmakta ve literatürdeki veriler ışığında ilgili bulgular sunulmaktadır. Materyal-Metod: Mart 2019-Eylül 2021 tarihleri ​​arasında malignite nedeniyle akciğer rezeksiyonu yapılan hastalar retrospektif olarak incelendi. Yaş, cinsiyet, ameliyat öncesi kemoterapi uygulamasının varlığı, yapılan ameliyatlar, ameliyat tarihleri, patoloji sonuçları, ameliyat sonrası evreleme, sağkalım ve nüksleri içeren hasta verileri belgelendi. Bu çalışma için etik onay Ankara Bilkent Şehir Hastanesi etik kurulundan alınmıştır. Onay numarası E1-20-817'dir. Bulgula